4-Hydroxydocosa-5,7,10,13,16,19-hexaenoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-Hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
• 化学式: C₂₂H₃₂O₃
• 分子量: 344.5
• InChiKey: IFRKCNPQVIJFAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  25
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] METHOD OF SYNTHESIZING A 5-OXO-CONJUGATED FATTY ACID<br/>[FR] PROCÉDÉ DE SYNTHÈSE D'UN ACIDE GRAS 5-OXO-CONJUGUÉ
  申请人：UNIV SYDDANSK

  公开号：WO2011131619A1

  公开（公告）日：2011-10-27

  There is provided a novel chemical synthetic method for the preparation of a 5-oxo-ETE and related compounds. The method is based on a short and efficient synthesis of 5-oxo-ETE from commercially available Arachidonic acid. The method is based on the surprising discovery that a 5-oxo-conjugated fatty acid may be efficiently converted into the corresponding 5-oxo-conjugated fatty acid by reaction with the Dess-Martin reagent (1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one)in the presence of pyridine or a substituted pyridine.

  提供了一种新颖的化学合成方法，用于制备5-氧-ETE及相关化合物。该方法基于从商业可获得的花生四烯酸中短而高效地合成5-氧-ETE。该方法基于一个惊人的发现，即5-氧共轭脂肪酸可以通过与Dess-Martin试剂（1,1,1-三乙酰氧基-1,1-二氢-1,2-苯碘氧醇-3(1H)-酮）在吡啶或取代吡啶的存在下反应，高效地转化为相应的5-氧共轭脂肪酸。
• THERAPEUTIC AGENT FOR ULCERATIVE COLITIS AND/OR CROHN'S DISEASE
  申请人：Yamamoto, Keiko

  公开号：EP1946754A1

  公开（公告）日：2008-07-23

  Disclosed is an agent for preventing or treating ulcerative colitis, Crohn's disease, and/or Behcet's disease. A therapeutic agent for ulcerative colitis, Crohn's disease, and/or Behcet's disease, comprising a polyunsaturated fatty acid derivative represented by the following formula (1) as an active ingredient.

  本发明公开了一种用于预防或治疗溃疡性结肠炎、克罗恩病和/或白塞氏病的制剂。一种治疗溃疡性结肠炎、克罗恩病和/或白塞氏病的药剂，由下式（1）代表的多不饱和脂肪酸衍生物作为活性成分组成。
• SYNTHESIS OF RESOLVINS AND INTERMEDIATES, COMPOUNDS PREPARED THEREBY, AND USES THEREOF
  申请人：Rodriguez Ana

  公开号：US20100159540A1

  公开（公告）日：2010-06-24

  Methods are disclosed for the preparation of a new class of lipid mediators known as resolvins, with Resolvin D6 (4,17-dihydroxy-5E,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid) being exemplary. Also disclosed are methods for the efficient synthesis of key intermediates in the preparation of such resolvins, such as isotopically labeled ω-3 fatty acid metabolites, and derivatives and analogs thereof. The invention likewise extends to the intermediates so prepared, and to the resolvins prepared with their use.
• [EN] SYNTHESIS OF RESOLVINS AND INTERMEDIATES, COMPOUNDS PREPARED THEREBY, AND USES THEREOF<br/>[FR] SYNTHÈSE DE RÉSOLVINES ET D'INTERMÉDIAIRES, COMPOSÉS PRÉPARÉS PAR CETTE SYNTHÈSE ET LEURS UTILISATIONS
  申请人：UNIV NEW JERSEY MED

  公开号：WO2008118457A2

  公开（公告）日：2008-10-02

  [EN] Methods are disclosed for the preparation of a new class of lipid mediators known as resolvins, with Resolvin D6 (4,17-dihydroxy-5E,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid) being exemplary. Also disclosed are methods for the efficient synthesis of key intermediates in the preparation of such resolvins, such as isotopically labeled ?-3 fatty acid metabolites, and derivatives and analogs thereof. The invention likewise extends to the intermediates so prepared, and to the resolvins prepared with their use.
  [FR] L'invention concerne des procédés de préparation d'une nouvelle classe de médiateurs lipides nommés résolvines, la résolvine D6 (acide 4,17-dihydroxy-5E,7Z,10Z,13Z,15E,19Z-docosahexaénoïque) en étant un exemple. L'invention concerne également des procédés efficaces de synthèse d'intermédiaires clés pour la préparation de telles résolvines, par exemple les métabolites d'acide gras ?-3 isotopiquement marqués et leurs dérivés et analogues. L'invention concerne également les intermédiaires ainsi préparés et les résolvines préparées en les utilisant.